Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 27042

1.

Role of Diffusional Kurtosis Imaging in Differentiating Neuromyelitis Optica-Related and Multiple Sclerosis-Related Acute Optic Neuritis: Comparison With Diffusion-Weighted Imaging.

Lu P, Yuan T, Liu X, Tian G, Zhang J, Sha Y.

J Comput Assist Tomogr. 2020 Jan/Feb;44(1):47-52. doi: 10.1097/RCT.0000000000000974.

PMID:
31939881
2.

[Clinical and urodynamic risk factors of recurrent urinary tract infections in patients with multiple sclerosis.]

Salinas-Casado J, Vírseda-Chamorro M, Méndez-Rubio S, López-Pérez E, Esteban-Fuertes M, Moreno-Sierra J, Guiu-Antem M, Pytel V, Montero-Escribano P, Matías-Guiu Guía J.

Arch Esp Urol. 2019 Dec;72(10):1010-1017. Spanish.

PMID:
31823849
3.

Evaluation of clinical prognostic factors in Polish interferon beta-1b treated multiple sclerosis patients.

Pietrzak A, Kalinowska-Łyszczarz A, Kozubski W, Michalak S.

Neurol Neurochir Pol. 2019;53(6):458-465. doi: 10.5603/PJNNS.a2019.0060. Epub 2019 Dec 3.

PMID:
31793659
4.

The Influence of Contrast-to-Noise Ratio on the Discrimination Between Cortical and Juxtacortical Lesions in Multiple Sclerosis.

Girolamo C, Filice S, Graziuso S, Francesca T.

J Comput Assist Tomogr. 2019 Nov/Dec;43(6):958-962. doi: 10.1097/RCT.0000000000000939.

PMID:
31738211
5.

Early MRI predictors of prognosis in multiple sclerosis.

Davda N, Tallantyre E, Robertson NP.

J Neurol. 2019 Dec;266(12):3171-3173. doi: 10.1007/s00415-019-09589-2. No abstract available.

6.

Decreased plasma levels of 25(OH)D in multiple sclerosis patients. Correlation with disease severity expressed by EDSS, MSSS, progression index and Herbert´s scale severity grade.

Bucova M, Durmanova V, Cudrakova D, Blazickova S, Gmitterova K, Klimova E, Lisa I, Kluckova K, Majernikova B.

Bratisl Lek Listy. 2019;120(10):723-729. doi: 10.4149/BLL_2019_120.

PMID:
31663345
7.

Burden of relapsing-remitting multiple sclerosis on workers in the US: a cross-sectional analysis of survey data.

Nicholas JA, Electricwala B, Lee LK, Johnson KM.

BMC Neurol. 2019 Oct 28;19(1):258. doi: 10.1186/s12883-019-1495-z.

8.
9.

[Multiple Sclerosis: Neurorehabilitation and Symptomatic Treatment].

Sailer M, Lindquist S, Sickert A, Lamprecht J.

Rehabilitation (Stuttg). 2019 Oct;58(5):339-350. doi: 10.1055/a-0755-1398. Epub 2019 Oct 23. German.

PMID:
31645080
10.

Putting multiple sclerosis on the genomic map.

Wood H.

Nat Rev Neurol. 2019 Dec;15(12):686-687. doi: 10.1038/s41582-019-0279-9. No abstract available.

PMID:
31619774
11.

Effects of crocin in reducing DNA damage, inflammation, and oxidative stress in multiple sclerosis patients: A double-blind, randomized, and placebo-controlled trial.

Ghiasian M, Khamisabadi F, Kheiripour N, Karami M, Haddadi R, Ghaleiha A, Taghvaei B, Oliaie SS, Salehi M, Samadi P, Ranjbar A.

J Biochem Mol Toxicol. 2019 Dec;33(12):e22410. doi: 10.1002/jbt.22410. Epub 2019 Oct 16.

PMID:
31617649
12.

Unraveling susceptibility to multiple sclerosis.

Briggs F.

Science. 2019 Sep 27;365(6460):1383-1384. doi: 10.1126/science.aay1439. No abstract available.

PMID:
31604260
13.

Functional and self-care capacity of people with multiple sclerosis.

Oliveira-Kumakura ARS, Bezutti LM, Silva JLG, Gasparino RC.

Rev Lat Am Enfermagem. 2019 Oct 7;27:e3183. doi: 10.1590/1518-8345.3068.3183. eCollection 2019. English, Portuguese, Spanish.

14.

Commentary re: Multiple sclerosis and psychosis: A case report. Cheema J, Huyh AC, Prat SS. 2019 Jun 3;34:158-161.

Greenberg R.

Mult Scler Relat Disord. 2019 Nov;36:101404. doi: 10.1016/j.msard.2019.101404. Epub 2019 Sep 21. No abstract available.

PMID:
31585304
15.

Meta-analysis of FOXP3 gene rs3761548 and rs2232365 polymorphism and multiple sclerosis susceptibility.

Zhang Y, Zhang J, Liu H, He F, Chen A, Yang H, Pi B.

Medicine (Baltimore). 2019 Sep;98(38):e17224. doi: 10.1097/MD.0000000000017224.

16.

Comparison of psychiatric disturbances in patients with multiple sclerosis and neuromyelitis optica.

Shin JS, Kwon YN, Choi Y, Lee JY, Lee YI, Hwang JH, Choi SH, Kim SM.

Medicine (Baltimore). 2019 Sep;98(38):e17184. doi: 10.1097/MD.0000000000017184.

17.

The association between gait variability with the energy cost of walking depends on the fall status in people with multiple sclerosis without mobility aids.

Kalron A, Frid L, Menascu S, Givon U.

Gait Posture. 2019 Oct;74:231-235. doi: 10.1016/j.gaitpost.2019.09.021. Epub 2019 Sep 21.

PMID:
31563824
18.

Increase of CSF inflammatory profile in a case of highly active multiple sclerosis.

Magliozzi R, Marastoni D, Rossi S, Castellaro M, Mazziotti V, Pitteri M, Gajofatto A, Monaco S, Benedetti MD, Calabrese M.

BMC Neurol. 2019 Sep 26;19(1):231. doi: 10.1186/s12883-019-1455-7.

19.

Multiple sclerosis and migration revisited.

Hawkes CH, Giovannoni G, Lechner-Scott J, Levy M, Waubant E (Chief editors).

Mult Scler Relat Disord. 2019 Sep;34:A1-A2. doi: 10.1016/j.msard.2019.08.001. Epub 2019 Aug 1. No abstract available.

PMID:
31543261
20.

A single T cell epitope drives the neutralizing anti-drug antibody response to natalizumab in multiple sclerosis patients.

Cassotta A, Mikol V, Bertrand T, Pouzieux S, Le Parc J, Ferrari P, Dumas J, Auer M, Deisenhammer F, Gastaldi M, Franciotta D, Silacci-Fregni C, Fernandez Rodriguez B, Giacchetto-Sasselli I, Foglierini M, Jarrossay D, Geiger R, Sallusto F, Lanzavecchia A, Piccoli L.

Nat Med. 2019 Sep;25(9):1402-1407. doi: 10.1038/s41591-019-0568-2. Epub 2019 Sep 9.

PMID:
31501610

Supplemental Content

Loading ...
Support Center